POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: POL6326|DRUG: Eribulin|DRUG: Nab paclitaxel
Sponsor: MedSIR